About
The Metabolomics Innovation Resource (MIR) at the Goodman Cancer Institute (GCI) is the primary node of a three-facility network (GCI, U Ottawa, Van Andel Research Institute) that specializes in metabolism and the measurement of small molecule metabolites. MIR is a multi-platform facility equipped with mass spectrometry, Seahorse (in-vivo respiration), and Nova Bioprofiling instrumentation. In addition to standard metabolite characterization, highly experienced platform scientists develop new technologies in response to researchers’ needs and offer workshops and one-on-one training to their users.
Leadership Team
Scientific Director
Peter Siegel, PhD
Platform Manager
Daina Avizonis, PhD
Tags: Metabolomics Core Facility, McGill Goodman Cancer Institute, GCI, Agilent, Bruker, NMR, GC/MS, LC-MS, LC-MS/MS, Seahorse XFe24, Seahorse XFe96, Seahorse Xfp, BioProfile 400
